#5
10/087,190 - FILED - CERTIFIED


511582003420

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 143875517 US

Date of Deposit: January 28, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Box Missing Parts, Washington, D.C. 20231.


Tami M. Procopio**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Pia M. CHALLITA-EID et al.

Serial No.: 10/087,190

Filing Date: February 28, 2002

For: NUCLEIC ACID AND CORRESPONDING
PROTEIN ENTITLED 121P1F1 USEFUL
IN TREATMENT AND DETECTION OF
CANCER

Examiner: To be assigned

Group Art Unit: To be assigned

**RESPONSE TO NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL
APPLICATION****BOX MISSING PARTS**Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to File Missing Parts of Nonprovisional Application mailed October 28, 2002, for which a response was due on December 28, 2002. Accordingly, a request and a petition for extension of time from December 28, 2002 to January 28, 2003, is included herewith.

Please enter the following sequence listing, amendments and remarks.

sd-127007

10/087,190

511582003420

In the Sequence Listing

Please insert a paper copy of the sequence listing as new pages 1- 30 in the above-mentioned patent application. A computer readable form copy of the sequence listing accompanies this response.

sd-127007

2

10/087,190

511582003420

AMENDMENTS

Substitute Specification

Please enter the following substitute specification, submitted in compliance with 37 CFR 1.125(b) and CFR 1.52(e). A marked-up version of the specification accompanies this response.

sd-127007

3

10/087,190

REMARKS

As required by 37 C.F.R. 1.125(b) Applicants have enclosed a substitute specification in response to the Notice to File Missing Parts of Nonprovisional Application dated October 28, 2002. As to the substitute specification, Applicants submit that no new matter was added. Enclosed is a marked up version showing all the changes to the specification of record. In addition, the specification in clean form without markings as to the amended material is also enclosed.

In the substitute specification, Applicants have inserted all the appropriate sequence identification numbers and deleted any mislabeled or unnecessary sequence identification numbers placed in the application as-filed. The drawings have been corrected to comply with 7 C.F.R. § 1.84 and 1.121. In addition, all hyperlinks have been deleted. No new matter was added.

Moreover, 37 C.F.R. § 1.821(d) indicates that, “[w]here the description or claims of a patent application discuss a sequence that is set forth in the ‘Sequence Listing’, reference must be made to the sequence by the use of a sequence identifier.” Further, MPEP §2422.03 states, “[s]equence identifiers can also be used to discuss and/or claim parts or fragments of a properly presented sequence.”

Thus, in Tables V-XVIII and XXII - LI Applicant's have inserted language that uses sequence identifiers to discuss fragments of the Figure 2 amino acids by the language: “Portion of SEQ ID NO X; where each start position is specified, the stop position of each peptide is the start position plus (A-1), where “A” is the length of each peptide (either 9, 10, or 15 as specified in each respective Table) and “X” refers to a particular amino acid sequence of Figure 2.

Finally, Applicants provide a copy of the Sequence Listing in Computer Readable Form (CRF) on CD-ROM. The undersigned hereby states that the compact disc copy of the Sequence Listing and the computer readable form copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

511582003420

In the unlikely event that the patent office determines that extensions and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the assistant commissioner to charge the cost of such petitions and/or fees due to our deposit account no. 03-1952 under order no. 511582003420. The assistant commissioner is not authorized to charge the cost of the issue fee to the deposit account.

Respectfully submitted,

Dated: January 28, 2003

By: Kate H. Murashige
Kate H. Murashige
Registration No. (29,959)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

sd-127007

5

10/087,190